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o the Results of the
erman Pilot Phase of the
uroCMR Registry Indicate That
he Chasm Has Been Crossed?
eoffrey Moore (1) in his landmark book about the technology
doption lifecycle, “Crossing the Chasm,” divides the adopters into
phases—innovators, early adopters, the early majority, the late
ajority, and the laggards—with the curve forming a typical
istribution curve with the major hump comprising the early and
he late majority. Psychologically, others have classified these
roups as technology enthusiasts (innovators), visionaries (early
dopters), pragmatists (early majority), conservatives (late major-
ty), and skeptics (laggards). Moore proposed that, for various
easons, there exists a chasm between the early adopters and the
arly majority and the success of any technological innovation
epends on the capability of the technology to cross this chasm.
The results of the EuroCMR (European Cardiovascular Mag-
etic Resonance) Registry (2) seem to suggest that, at least in
ermany, cardiac magnetic resonance imaging (MRI) has been
ble to cross this chasm with its value being understood and
xploited for improving clinical care. Until now cardiac MRI has
emained a niche exam with numerous cardiac MRI units per-
orming studies for patients with congenital heart disease, cardiac
asses, pericardial disease, aortic pathology, and angiography. The
se of cardiac MRI in cardiomyopathies and ischemic heart disease
as clearly changed the status of this technique in our diagnostic
rmamentarium. Because ischemic heart disease comprises the
argest component of patients in contemporary clinical practice,
he use of cardiac MRI in this arena for ischemia and viability
ssessment would seem to suggest that cardiac MRI has “crossed
his chasm” and is now believed to be ready for primetime by
ardiologists who do not perform cardiac MRI (because they
ould comprise the early and the late majority in Moore’s
escription).
To be sure this has happened, which is welcome. Given the
otential of this technique, we wish to clarify the following points: p. Of the referrals made, how many were made by physicians who
actively perform cardiac MRI and by those who do not perform
cardiac MRI? This information would eliminate the potential
for a referral bias by those who perform this technique. In
23.1% of patients, cardiac MRI was the first technique or-
dered—who referred these patients? We consider any referral
from any member of any cardiac MRI group to be a potential
self-referral—this could simply mean that those who perform
the technique might be able to decide which patient might be
best suited for a cardiac MRI study.
. In the subgroup of those who underwent cardiac MRI as the
first study, all imaging needs were satisfied in 80.3%. Some
information in the remaining 20% who required further studies
would be helpful for understanding the limitations of cardiac
MRI.
. We are also interested to know the reasons why 11% of those
who underwent viability assessment by cardiac MRI still re-
quired a subsequent transthoracic echocardiography, because
cardiac MRI is now considered the practical gold standard for
viability assessment. We acknowledge that the reasons might be
other than viability assessment.
. A total of 5,025 patients in the centers in the registry
underwent cardiac MRI for suspected coronary artery disease/
ischemia assessment and determination of viability. It would be
very informative to know the number of single-photon emission
computed tomography and echocardiographic studies ordered
in these centers for the same reasons, because this would reflect
the positioning of the cardiac MRI study in the routine clinical
practice in the centers that participated in the registry.
The authors have made a laudable effort in extending the use of
very valuable technique. If the clarifications we request indicate
hat the chasm has not been crossed by cardiac MRI, we hypoth-
size that the presentation of prognostic data based on cardiac
RI studies might be the eventual trigger and the authors have
ccurately emphasized the need for extension of their work.
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eply
e deeply appreciate Drs. Thomas and Tavares’ interest in our paper
1) and welcome their important points for further clarification.
We easily admit that some of us are enthusiasts (innovators),
ome are even visionaries (early adopters), but the majority are very
ragmatic people who want cardiac magnetic resonance (CMR) to
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January 26, 2010:408–13escend from its “Magic Mountain.” We also admit that none of
he authors can be addressed as conservative (can science be
onservative anyway?).
The basic aim of this registry is to let the clinical cardiologist be
ware that CMR is not only ready to answer relevant questions
egarding specific research and clinical aspects of cardiology but
hat the use of this technology has the potential to substantially
hange and improve everyday clinical practice. This purpose can be
btained only by analyzing a large database where data from a
iffuse network of clinical centers can be collected. Thus, the
resent article is unavoidably preliminary, and the term “pilot-
tudy” in the report’s title was used to underscore this point.
Unfortunately, the data necessary for clarifications requested by
he authors were not collected during the pilot phase of the
egistry. However, we agree that this information would be
nteresting to collect in future specific protocols.
Nevertheless, with regard to more than 60 requests for partic-
pation in the multinational phase of the EuroCMR Registry from
enters all over Europe currently being processed by the Institut fürerzinfarktforschung, we have some hope that CMR has already
rossed the chasm in Europe.
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